Escala de Gravidade e Habilidade Funcional para pacientes com Esclerose Lateral Amiotrófica:

Resultados Preliminares

Autores

  • Marco Orsini Physical Therapist, Chair of the Neurological Rehabilitation, Escola Superior de Ensino Helena Antipoff (ESEHA) and Neuroscience Researcher at UFF.
  • Marcos RG de Freitas Neurologist, Chair of the Neurology Department and Head of Clinical Neurology Staff, UFF.
  • Mariana Pimentel de Mello Physical therapist, Department of Neuroscience, UFF.
  • Clayton Amaral Domingues Neuropsychiatry Institute, Instituto de Psiquiatria da Universidade do Brasil, UFRJ.
  • José Mauro Brás Lima Neurolgist, Neurology Department, Deolindo Couto Neurology Institute, UFRJ.
  • Marli Pernes Neurolgist, Neurology Department, Deolindo Couto Neurology Institute, UFRJ.
  • Cláudio Heitor Gress Neurolgist, Neurology Department, Deolindo Couto Neurology Institute, UFRJ.
  • Acary Souza Bulle Oliveira MD, PhD, Neurologist, Department of Neurology, Unifesp.
  • Carlos Henrique Melo Reis Neurologist, Neurology Department, UFF.
  • Wandilson Wandilson Júnior Neurologist, Neurology Department, UFF.
  • Giseli Quintanilha Neurologist, Neurology Department, UFF.
  • Eduardo B Cavalcanti Medical Student, UFF.
  • Luciane Bizari Coin de Carvalho PhD, Psychologist, Neuro-Sono, Department of Neurology, Universidade Federal de São Paulo.

DOI:

https://doi.org/10.34024/rnc.2008.v16.8632

Palavras-chave:

Esclerose Lateral Amiotrófica, Escalas, Doenças Neuromusculares

Resumo

Introdução. A esclerose lateral amiotrófica (ELA) é uma doença progressiva e fatal que afeta os neurônios do feixe piramidal e da ponta anterior da medula espinhal. Inúmeras avaliações têm sido propostas no sentido de fornecer um melhor acompanhamento dos indivíduos e gerenciamento das complicações secundárias. Apresentamos, no presente estudo, um novo instrumento para acompanhamento clínico e reabilitativo de pacientes com ELA. Método. Avaliamos 96 pacientes consecutivos com diagnóstico de ELA, no Hospital Universitário Antonio Pedro e no Instituto de Neurologia Deolindo Couto com a Escala de Gravidade e Habilidade Funcional. Resultados. Estes dados preliminares permitiram delinear uma escala de 5 domínios que mensuram 1) força muscular em miótomos específicos, 2) habilidades funcionais, 3) deglutição 4) respiração, and 5) estágio de gravidade da doença. As características clínicas e manifestações funcionais dos pacientes com ELA foram heterogêneas em relação as complicações mais freqüentes e ao nível de independência funcional. Conclusão. Estes resultados preliminares sugerem que nossa escala de 5 domínios é simples, de fácil aplicabilidade, não demorada, assim como facilmente reprodutível a respeito do curso clínico e do prognóstico dos pacientes com ELA. Nosso estudo piloto garante a etapa seguinte de nossa pesquisa que inclui a exatidão, validade interna, a confiabilidade, análise fatorial e outros procedimentos
metodológicos e estatísticos formais necessários.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model of survival prediction. Brain 1995;118:707-19.

Rosenfeld J, Jackson CE. Quantitative assessment and outcome measures in neuromuscular disease. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE (eds.) Neuromuscular Disorders in Clinical Practice. Boston: Butterworth Heinemann, 2002, 1416p.

Guccione AA. Physical therapy diagnosis and the relationship between impairments and function. Phys Ther 1991;71:499-504.

Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 2004;1(2): 273-83.

Stambler N, Charatan M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology 1998;50:66-72.

Damiano AM, Patrick DL, Guzman GI, Gawel MJ, Gelinas DF, Natter HM, et al. Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies. Med Care 1999;37(1): 15-26.

Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revised: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotr Lat Scler Other Motor Neuron Disord 2000;1(5):293-9.

Medical Research Council. Aids to the examination of the peripheral nervous system. Edinburgh: WB Saunders, 2000, 1-2.

Czaplinski A, Yen AA, Appel SH. Amyotrophic Lateral Sclerosis: early predictors of prolonged survival. J Neurol 2006; 253:1428-36.

Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology 2005;64:1215-21.

Del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-9.

Brooks BR. Clinical epidemiology of amyotrophic lateral sclerosis. Neurol Clin 1996:14:399-420.

Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-15.

Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-64.

Werneck LC, Bezerra R, Neto OS, Scola RH. A clinical epidemiological study of 251 cases of amyotrophic lateral sclerosis in the south of Brazil. Arq Neuropsiquiatr 2007;65(2A):189-95.

Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: prepare for the worst and hope for the best. JAMA 2007;298(2):207-16.

Pozza AM, Delamura MK, Ramirez C, Valério NI, Marino LHC, Lamari NM. Physiotherapeutic conduct in amyotrophic lateral sclerosis. São Paulo Med J 2006;124(6):350-4.

Miller RG, Anderson FA, Bradley WG, Brooks BR, Mitsumoto H, Munsat TL, et al. The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group. Neurology 2000;54(1):53-7.

Trifirò G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, et al. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004, Pharmacoepidemiol Drug Saf 2007;16(5):552-9.

Gordon T, Hegedus J, Tam SL. Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 2004;26(2):174-85.

Swash M, Schwartz MS. What do we really know about amyotrophic lateral sclerosis? J Neurol Sci 1992;113:4-16.

Vainstein G, Gordon C, Gadoth N. HTLV-1 Associated Motor Neuron Disease Mimicking “Man-in-the-Barrel” Syndrome. Journal of Clinical Neuromuscular Disease 2005;6(3):127-31.

Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003;61:1503-7.

Gooch CL, Shefner JM. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl 1):104-7.

Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 1999;53:1239-46.

Wagner-Sonntag E, Prosiegel M. Dysphagia. In: Ollver D, Borasio GD, Walsh D (eds.). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2 ed. Oxford: Oxford University Press, 2006, 95-109.

Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 1999;169:118-25.

Kubler A, Nijboer F, Mellinger J, 6 autores, et al. Patients with ALS can use sensoriomotor rhythms to operate a brain-computer interface. Neurology 2005;64:1775-7.

Belsh JM, Schiffman PL (eds.). Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk. New York: Futura, 1996, 41-3.

Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan /quinidine: a randomized trial. Neurology 2004;63:1364-70.

Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M. Home ventilator for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family and physician attitudes. Neurology 1993;43:438-43.

Desnuelle C, Bruno M, Soriani MH, Perrin C. Quelles sont les modalités de thérapie physique symptomatique incluant les techniques de désencombrement bronchique? Rev Neurol (Paris) 2006;162(2):4S244-52.

Downloads

Publicado

2008-09-30

Como Citar

Orsini, M., Freitas, M. R. de, Mello, M. P. de, Domingues, C. A., Lima, J. M. B., Pernes, M., … Carvalho, L. B. C. de. (2008). Escala de Gravidade e Habilidade Funcional para pacientes com Esclerose Lateral Amiotrófica:: Resultados Preliminares. Revista Neurociências, 16(3), 194–203. https://doi.org/10.34024/rnc.2008.v16.8632

Edição

v. 16 n. 3 (2008)

Seção

Artigos Originais
##plugins.generic.dates.received## 2019-03-05
##plugins.generic.dates.published## 2008-09-30

Artigos mais lidos pelo mesmo(s) autor(es)

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

Artigos Semelhantes

1 2 3 4 5 6 7 8 9 10 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.